Literature DB >> 8496866

The natural history of ankylosing spondylitis. Does it burn out?

L G Kennedy1, L Edmunds, A Calin.   

Abstract

Initially, 1,492 patients with ankylosing spondylitis (AS) were assessed by a new disease activity index. This addressed the degree of pain, severity and overall disease activity (scale 3-26). As expected, there was a normal distribution with a median of 12. Sixty-five patients, selected from the extremes of the disease activity scale, (< 5, > 22), were prospectively followed over a 2-year period: 30 with high activity mean score 24.1 (SD 1.2) and 35 with low mean score 3.4 (SD 0.5). At followup, subjects were assessed with this new index and a validated functional index. Although at followup the high activity mean score was significantly reduced to 21.1 (p < 0.001) and the low activity mean score was significantly increased to 6.1 (p = 0.002), the majority of the patients had remained in their original quartiles i.e., 63 and 77%, respectively. Disease status at followup was independent of disease duration; i.e., high activity group mean 27.1 (SD 5.3) and remission group 26.9 (SD 13.77) years, respectively (NS). When the 2 disease indices were compared, an excellent correlation existed: r = 0.788, p < 0.001. Our data suggest (1) < 1% of patients with AS who present to a rheumatologist enter longterm remission ("burn out"). (2) Some 20% of patients in remission will develop active disease 2 years later. (3) The prognosis over 2 years for those with active disease is poor.

Entities:  

Mesh:

Year:  1993        PMID: 8496866

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts.

Authors:  Fernando M Pimentel-Santos; Ana Filipa Mourão; Célia Ribeiro; José Costa; Helena Santos; Anabela Barcelos; Patricia Pinto; Fátima Godinho; Margarida Cruz; Elsa Vieira-Sousa; Rui André Santos; Sara Rabiais; Jorge Félix; João Eurico Fonseca; Henrique Guedes-Pinto; Matthew A Brown; Jaime C Branco
Journal:  Clin Rheumatol       Date:  2011-10-19       Impact factor: 2.980

2.  Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis.

Authors:  Z N Tutuncu; A Bilgie; L G Kennedy; A Calin
Journal:  Ann Rheum Dis       Date:  1994-06       Impact factor: 19.103

3.  Adalimumab-induced lupus serositis.

Authors:  Dearbhla Kelly; Oisin O'Connell; Michael Henry
Journal:  BMJ Case Rep       Date:  2015-03-04

4.  A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity.

Authors:  Yesim Akkoc; Altinay Goksel Karatepe; Servet Akar; Yesim Kirazli; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2004-01-17       Impact factor: 2.631

5.  Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Authors:  A Calin; B A C Dijkmans; P Emery; M Hakala; J Kalden; M Leirisalo-Repo; E M Mola; C Salvarani; R Sanmartí; J Sany; J Sibilia; J Sieper; S van der Linden; E Veys; A M Appel; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

6.  Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings.

Authors:  L Goh; P Suresh; A Gafoor; P Hughes; P Hickling
Journal:  Clin Rheumatol       Date:  2007-10-02       Impact factor: 2.980

7.  Symptomatic improvement in function and disease activity in a patient with ankylosing spondylitis utilizing a course of chiropractic therapy: a prospective case study.

Authors:  Susan M Rutherford; Cameron F Nicolson; Edward R Crowther
Journal:  J Can Chiropr Assoc       Date:  2005-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.